Allergan’s SpotLyte and Lumivive System


Sep. 28 2018, Updated 12:55 p.m. ET

Allergan’s announcements

On September 12, Allergan (AGN) announced the launch of SpotLyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. On September 6, Allergan announced the launch of its dual-acting product, the SkinMedica Lumivive System.

Article continues below advertisement


SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics. SpotLyte is a digital hub designed to help consumers determine how medical aesthetic treatments may fit their routines. The site is designed with the goal of providing well-researched and accurate information.

The brand-agnostic site is designed to provide unbiased information to consumers. The site also has a chat feature that connects consumers with specialists for information about the treatments and local licensed providers.


The SkinMedica Lumivive System is a skincare product that is designed to work as a shield from blue light during the day and works as a skin repair product at night. According to the company, the Lumivive System offers atmospheric protection during the day and fights signs of aging.

Allergan noted that Lumivive is designed to work with the existing SkinMedica products such as HA5 Rejuvenating Hydrator, TNS Essential Serum, and Total Defense and Repair broad-spectrum sunscreens.

The Invesco Dynamic Pharmaceuticals ETF (PJP) holds 3.0% in Allergan (AGN), 5.6% in Eli Lilly & Co. (LLY), 4.9% in Gilead Sciences (GILD), and 2.9% in Biogen (BIIB).


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.